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PPRECLINICAL STUDY
Therapy With Cardiac Contractility Modulation
Electrical Signals Improves Left Ventricular Function
and Remodeling in Dogs With Chronic Heart Failure
Makoto Imai, MD,* Sharad Rastogi, MD,* Ramesh C. Gupta, PHD,* Sudhish Mishra, PHD,*
Victor G. Sharov, MD, PHD,* William C. Stanley, PHD,† Yuval Mika, PHD,‡ Benny Rousso, PHD,‡
Daniel Burkhoff, MD, PHD, FACC,‡ Shlomo Ben-Haim, MD, PHD,‡ Hani N. Sabbah, PHD, FACC*
Detroit, Michigan; Cleveland, Ohio; and Orangeburg, New York
Objectives This study examined the effects of long-term delivery of cardiac contractility modulation (CCM) electric signals on left
ventricular (LV) function and global, cellular, and molecular remodeling in dogs with chronic heart failure (HF).
Background Acute studies in dogs with experimentally induced HF showed that CCM signals applied to the failing myocar-
dium during the absolute refractory period improved LV function without increasing myocardial oxygen consump-
tion.
Methods In one study, dogs with intracoronary microembolization-induced HF were randomized to 3 months of active
CCM monotherapy or to a sham-operated control group. In another study, 19 HF dogs were randomized to 3
months chronic monotherapy with extended release metoprolol succinate (MET-ER), MET-ER with CCM, or no
therapy at all (control group).
Results In CCM-only treated dogs, LV ejection fraction (EF) increased (27  1% vs. 33  1%, p  0.0001) compared
with a decrease in sham-operated control animals (27  1% vs. 23  1%, p  0.001). The increase in EF seen
with CCM-treated dogs was accompanied by reduced LV volumes, improved myocardial structure, reversal of the
maladaptive fetal gene program, and an improvement in sarcoplasmic reticulum calcium cycling proteins. Dogs
treated with a combination of MET-ER and CCM showed a greater increase in LV EF and a greater reversal of LV
global, structural, and biochemical remodeling compared with dogs treated with MET-ER alone.
Conclusions In dogs with HF, long-term CCM therapy improves LV systolic function. The improvements are additive to those
seen with beta-blockers. These findings are further strengthened by the concomitant benefits of CCM therapy
on LV global, cellular, and biochemical remodeling. (J Am Coll Cardiol 2007;49:2120–8) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.082(
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Lespite improvements in pharmacologic therapy for chronic
eart failure (HF) (1–3), a large number of patients with
ew York Heart Association functional class III and IV are
efractory to optimal standard medical therapy. The need
or further therapeutic interventions in this patient popula-
ion has given rise to a host of device-based therapies such
s cardiac resynchronization therapy. Cardiac resynchroni-
ation therapy has been shown to improve left ventricular
rom the *Division of Cardiovascular Medicine, Henry Ford Heart and Vascular
nstitute, Detroit, Michigan; †Department of Physiology and Biophysics, Case
estern Reserve University, Cleveland, Ohio; and ‡Impulse Dynamics USA, Inc.,
rangeburg, New York. The study was supported, in part, by a research grant from
mpulse Dynamics USA, Inc. and by a grant from the National Heart, Lung, and
lood Institute, PO1 HL074237-03. Dr. Sabbah has research grant support from and
s a consultant to Impulse Dynamics USA, Inc. Drs. Mika, Rousso, Burkhoff, andi
en-Haim are full-time employees of Impulse Dynamics USA, Inc.
Manuscript received August 11, 2006; accepted October 1, 2006.LV) systolic function in a subset of patients with dyssyn-
hrony of myocardial contraction (4–7). Cardiac contractil-
ty modulation (CCM) electrical signals delivered to the
ailing myocardium during the absolute refractory period is
nother device-based therapy targeting this advanced HF
opulation (8). In dogs with chronic HF, CCM signals
pplied acutely via leads sutured directly to the LV epicar-
ium (9) or longer term via leads placed retrograde into the
oronary sinus and positioned in the anterior coronary vein
10) resulted in improved LV systolic function (9,10).
reliminary clinical studies of CCM signals delivered to the
yocardium of patients with chronic HF suggest that
CM therapy is safe and can also improve exercise tolerance
nd quality of life (11,12). In dogs with HF, classical
ositive inotropic agents such as dobutamine also improve
V systolic function but at a cost that the failing heart canll afford, namely, an increase in myocardial oxygen con-
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May 29, 2007:2120–8 CCM Therapy in HFumption (MVO2) (13). In contrast, acute delivery (2 h) of
CM therapy in dogs with chronic HF was associated with
mproved LV function and with no increase in MVO2 (8).
he purpose of this study was to determine: 1) whether
ong-term CCM monotherapy improves LV systolic
unction when used alone and in combination with a
eta-blocker; 2) whether CCM therapy elicits improve-
ent in LV remodeling both globally and at the cellular
nd molecular levels; and 3) potential mechanisms that
nderlie the improvement in LV function seen with
CM therapy.
ethods
nimal model. The dog model of chronic HF used in the
resent study was previously described in detail (14–16). In
his study, healthy mongrel dogs weighing between 20 kg
nd 30 kg underwent coronary microembolizations to pro-
uce HF. Microembolizations were performed during car-
iac catheterization under general anesthesia and sterile
onditions. Animals were induced with intravenous oxymor-
hone hydrochloride (0.22 mg/kg) and diazepam (0.17 mg/
g), and a plane of anesthesia was maintained with 1% to
% isoflurane. The study was approved by Henry Ford Health
ystem Institutional Animal Care and Use Committee.
mplantation of the CCM system. Two weeks after the
arget LV ejection fraction (EF) was reached, dogs were
nesthetized, intubated, and ventilated with room air. The
ight external jugular vein was surgically exposed and used
o position the CCM leads. Two standard active fixation
eads were advanced into the right ventricle, positioned on
Figure 1 Right Anterior Oblique Fluoroscopic Image of
Leads Placement During CCM System Implantation
CCM  cardiac contractility modulation.uhe anterior and posterior septal
rooves, and used to sense ven-
ricular activity and deliver CCM
lectrical signals. A third lead
as positioned in the right
trium for p-wave sensing (Fig.
). The leads were connected to a
CM signal generator (OPTI-
IZER II, Impulse Dynamics
SA, Inc., Orangeburg, New
ork) implanted in a subcutane-
us pocket created on the right
ide of the neck. As observed in
linical studies to date (8), there
as no induction of ventricular
r atrial ectopic beats, atrial fi-
rillation, or intercostal stimula-
ion. Diaphragmatic stimulation
as also avoided by testing signal
pplication during the implant
nd moving the leads if a prob-
em was observed. Studies were
nitiated 2 weeks after CCM sys-
em implantation to allow leads
o stabilize in place.
hronic study protocol—
onotherapy with CCM.
ourteen dogs were embolized to
chieve a target LV EF, deter-
ined angiographically, of
30%. Two weeks after device
mplantation, dogs underwent a
retreatment left and right heart
atheterization and were then
andomized to 3 months of ac-
ive treatment group (n  7) or
o a sham-operated control
roup (n  7). In the active
roup, CCM therapy was ad-
inistered for 5 h/day based on a
uty cycle of 1 h ON and 3 h and
8 min OFF for 3 months. Dur-
ng ON periods, CCM signals
ere delivered on every beat after a delay from the detection
f electrical activity at one of the right ventricular leads. As
etailed previously (12), the signals consisted of 2 biphasic
ulses having a total pulse width of 20.56 ms (10.28
s/pulse) with an amplitude of 7.73 V. Control dogs did
ot receive any therapy. At the end of 3 months of therapy
r follow-up, all hemodynamic measurements were re-
eated. Finally, while under general anesthesia, the chest
as opened and the heart rapidly harvested and tissue
repared for histological and biochemical evaluation. Tissue
rom 6 normal dogs were obtained and prepared in the same
anner for comparisons. All tissue was stored at 70oC
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
AR  adrenergic receptor
BNP  brain natriuretic
peptide
CCM  cardiac
contractility modulation
CD  capillary density
CSQ  calsequestrin
EDV  left ventricular end-
diastolic volume
EF  ejection fraction
ESV  end-systolic volume
GAPDH  glyceraldehyde-3-
phosphate dehydrogenase
HF  heart failure
LV  left ventricular
MCSA  myocyte cross-
sectional area
MET-ER  metoprolol
succinate-extended release
MHC  -myosin heavy
chain
MVO2  myocardial oxygen
consumption
ODD  oxygen diffusion
distance
PLB  phospholamban
P-PLB  phosphorylated
phospholamban
RyR  ryanodine receptor
SERCA-2a  sarcoplasmic
reticulum calcium ATPase
SR  sarcoplasmic
reticulum
VFIF  volume fraction of
interstitial fibrosis
VFRF  volume fraction of
replacement fibrosisntil needed.
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CCM Therapy in HF May 29, 2007:2120–8hronic study protocol—CCM in combination with
eta-blockade. To determine whether CCM therapy has
dded benefits when used in combination with a beta-
locker, 19 dogs with HF (LV EF between 30% and 40%)
ere randomized to 3 months CCM therapy delivered as
escribed above but in this case in combination with oral
xtended-release metoprolol succinate (MET-ER 100 mg
nce daily, n 7), MET-ER alone (100 mg once daily, n
), or to no therapy at all (control group, n  6). Hemo-
ynamic and angiographic measurements were made at
andomization and repeated at the end of 3 months, and LV
issue was obtained for analysis.
dditional acute protocol to assess mechanism of ac-
ion. To partly address mechanisms of action of CCM
herapy, 6 additional HF dogs were studied acutely with the
hest open via a midsternotomy. Epicardial CCM leads
ere placed on the anterior wall between the 2nd and 3rd
iagonal branches. Hemodynamic and angiographic mea-
urements were made before and 2 h after continuous CCM
ignal delivery at 7.73 V. At 2 h, myocardial samples were
btained from the LV anterior wall in the region of the
CM leads and from the LV posterior wall remote from the
CM leads. Left ventricular tissue from 6 normal dogs and
HF dogs that were untreated was also obtained and used
or comparisons.
emodynamic and ventriculographic measurements.
ortic and LV pressures were measured with catheter-tip
icromanometers (Millar Instruments, Houston, Texas)
uring cardiac catheterization. Left ventricular end-diastolic
ressure was measured from the LV waveform. Single-plane
eft ventriculograms were obtained as previously described
14–16). Left ventricular end-diastolic volume (EDV) and
nd-systolic volume (ESV) were calculated from ventricular
ilhouettes using the area-length method (17). Stroke vol-
me was calculated as the difference between EDV and
SV. Ejection fraction was calculated as the difference
etween EDV and ESV divided by EDV times 100.
rotein expression. Calsequestrin (CSQ), atrial natriuretic
eptide (ANP), brain natriuretic peptide (BNP), ryanodine
eceptor (RyR), total phospholamban (PLB), phosphory-
ated PLB (P-PLB) at serine 16 and threonine 17, sarco-
lasmic reticulum (SR) calcium ATPase (SERCA-2a), and
1-adrenergic receptor (AR) were measured in sodium
odecyl sulfate-LV homogenate prepared from LV powder
y Western blots as described previously (18,19). Total
-PLB was quantified in sodium dodecyl sulfate–
hosphoprotein-enriched fraction prepared from LV ho-
ogenate using PLB-specific monoclonal antibody (20).
and intensity was quantified using a Bio-Rad GS-670
maging densitometer and expressed as densitometric units
mm2.
RNA expression. The mRNA expression of glyceralde-
yde-3-phosphate dehydrogenase (GAPDH), -myosin
eavy chain (MHC), 1-AR, ANP, BNP, SERCA-2a,
LB, RyR, and CSQ was measured. Total RNA with an
bsorbance ratio (260 nm/280 nm) above 1.7 was isolated Erom frozen LV tissue, and approximately 4 g to 10 g
NA was reverse-transcribed into cDNA in an assay
olume of 80 l as described previously (20). The mRNA
xpression of -MHC was measured by amplification of
DNA by reverse transcriptase-polymerase chain reaction
ollowed by digestion with Pst1 restriction enzyme as
escribed previously (21). Fluorescent band intensity was
uantified using a Bio-Rad GS-670 imaging densitometer
nd expressed as optical density  mm2.
istomorphometric assessments. From each heart, 3
ransverse slices (approximately 3-mm thick), 1 each from
asal, middle, and apical thirds of the LV, were obtained.
or comparison, tissue samples obtained from 7 normal
ogs were prepared in an identical manner. From each slice,
ransmural tissue blocks were obtained and embedded in
araffin blocks. Transmural tissue blocks were also obtained
rom the free wall segment of the slice, mounted on cork
sing Tissue-Tek embedding medium (Sakura Finetek
.S.A. Inc., Torrance, California), and rapidly frozen in
sopentane precooled in liquid nitrogen and stored at
70oC until used. The volume fraction of replacement
brosis (VFRF), volume fraction of interstitial fibrosis
VFIF), myocyte cross-sectional area (MCSA), capillary
ensity (CD), and oxygen diffusion distance (ODD) were
easured as previously described (22–24).
ata analysis. To assess treatment effect, the change () in
ach measure from pretreatment (PRE) to post-treatment
POST) was calculated for each of the study groups and
hen the  compared between groups. For these compari-
ons, a t statistic for 2 means was used with a probability
alue 0.05 considered significant. Within-group compar-
sons between PRE and POST hemodynamic measures
ere made using a Student paired t test with a value of p 
.05 considered significant. Between-group comparisons
ere examined using 1-way analysis of variance with  set at
.05. If significance was achieved, pairwise comparisons
ere performed among groups using the Student-Newman-
uels test with a probability value of 0.05 considered
ignificant. All data are reported as the mean  SEM.
esults
indings with chronic CCM monotherapy. At baseline,
ll dogs entered into the study had hemodynamic measures
hat were within normal limits for conditioned mongrel
ogs in our laboratory. The hemodynamic and ventriculo-
raphic results obtained at PRE and POST are shown in
able 1. In sham-operated dogs, comparison of PRE to
OST showed no differences in heart rate, systolic aortic
ressure, LV end-diastolic pressure, or stroke volume. In
his group, LV EDV and ESV increased significantly while
V EF decreased significantly (Table 1). In CCM-treated
ogs, comparison of PRE to POST also showed no differ-
nces in heart rate and systolic aortic pressure. Left ventric-
lar end-diastolic pressure decreased as did LV EDV and
SV while stroke volume and EF increased. Comparison of
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May 29, 2007:2120–8 CCM Therapy in HF(treatment effect) between the 2 study groups showed no
hange of heart rate and systolic aortic pressure. Compared
ith sham-operated control animals, CCM-treated dogs
ad a significantly lower LV end-diastolic pressure, EDV,
nd ESV along with significantly higher LV EF and stroke
olume (Table 2).
Histomorphometric results are shown in Table 3. Vol-
me fraction of replacement fibrosis, VFIF, and MCSA
ere significantly higher in sham-operated dogs compared
ith normal dogs. Volume fraction of replacement fibrosis
as reduced by 23%, VFIF was reduced by 16%, and
CSA was reduced by 19% compared with sham-operated
ontrols. Capillary density decreased in sham-operated con-
rols while ODD increased when compared with normal
ogs. Cardiac contractility modulation therapy restored CD
nd ODD to near normal (Table 3).
The mRNA expression in LV free wall of the housekeep-
ng genes GAPDH and CSQ; the fetal program genes
onsisting of 1-AR, MHC, ANP, and BNP; and the
ardiac sarcoplasmic reticulum (SR) genes SERCA-2a,
LB, and RyR are shown in Table 4. Expression of
APDH and CSQ was unchanged among the 3 study
roups, namely, normal dogs, sham-operated HF dogs, and
F CCM-treated dogs. mRNA expression of 1-AR,
MHC, SERCA-2a, PLB, and RyR decreased, and expres-
ion of ANP and BNP increased significantly in sham-
Hemodynamic and Angiographic Findings in ShaDogs With Heart Failure Before and 3 Months Aor Follow-Up
Table 1
Hemodynamic and Angiographic Fin
Dogs With Heart Failure Before and
or Follow-Up
Sham-Control Do
PRE POST
Heart rate (beats/min) 89 4 101 7
Systolic AoP (mm Hg) 97 6 104 6
LV EDP (mm Hg) 13 1 14 1
LV EDV (ml) 67 2 77 2
LV ESV (ml) 49 2 60 2
LV EF (%) 27 1 23 1
Stroke volume (ml) 18 1 17 1
AoP  aortic pressure; CCM  cardiac contractility modulation; EDP 
ESV  end-systolic volume; LV  left ventricular; NS  not significant
reatment Effect*
Table 2 Treatment Effect*
Sham-Operated
Untreated HF Dogs
CCM-Treated
HF Dogs p Value
 Heart rate (beats/min) 12 8 8 4 NS
 Systolic aortic pressure
(mm Hg)
6 6 1 7 NS
 LV EDP (mm Hg) 1 2 6 2 0.029
 LV EDV (ml) 10 1 4 2 0.0001
 LV ESV (ml) 11 1 7 2 0.0001
 LV EF (%) 4 1 6 1 0.0001
 Stroke volume (ml) 1 0.5 3 0.4 0.0001
Comparison of the change () from pretreatment to post-treatment between sham-operated
ntreated heart failure (HF) dogs and CCM-treated HF dogs. p values based on comparison between
ham-operated and CCM-treated dogs.
Abbreviations as in Table 1.
f
vperated HF dogs compared with normal animals. Cardiac
ontractility modulation therapy restored the expression of
ll genes to near normal levels. Protein expression in the LV
ree wall is shown in Table 4. Protein levels of CSQ were
nchanged among the 3 study groups. Protein levels of
1-AR, SERCA-2a, PLB, and RyR decreased and that of
NP and BNP increased significantly in sham-operated
ontrol animals compared with normal animals. Cardiac
ontractility modulation therapy restored the expression of
ll measured proteins except PLB. The restoration genes
nd proteins after 3 months of CCM therapy were the same
n LV tissue obtained from the interventricular septum, the
ite nearest to the CCM signal delivery leads, and the LV
ree wall, a site remote from the CCM leads (Fig. 2).
rotein levels of P-PLB at serine-16 and threonine-17
ade in tissue obtained from both the interventricular
eptum and the LV free wall were significantly lower in
ham-operated HF dogs compared with normal dogs and
eturned to near normal levels after 3 months of CCM
herapy (Fig. 3, Table 5). In both the interventricular
eptum and LV free wall, the ratio of P-PLB at serine-16 to
otal PLB and the ratio of P-PLB at threnonine-17 were
lso significantly lower in sham-operated HF dogs com-
ared with normal dogs (Table 5). Long-term CCM
herapy resulted in a significant increase of both ratios in
erated and CCM-Treatednitiating Treatment
in Sham-Operated and CCM-Treated
onths After Initiating Treatment
CCM-Treated Dogs
Value PRE POST p Value
NS 78 3 87 3 NS
NS 101 4 102 5 NS
NS 14 1 8 1 0.01
.0001 70 6 66 5 0.08
.0001 52 6 45 4 0.008
.001 27 1 33 1 0.0001
NS 18 1 21 1 0.0001
iastolic pressure; EDV  end-diastolic volume; EF  ejection fraction;
pretreatment; POST  post-treatment.
hronic Histomorphometric Findings in Leftentricular Myocardium of Normal Dogs, Sham-perated Untreated HF Dogs, and CCM-TreatedF Dogs
Table 3
Chronic Histomorphometric Findings in Left
Ventricular Myocardium of Normal Dogs, Sham-
Operated Untreated HF Dogs, and CCM-Treated
HF Dogs
Normal Dogs
Sham-Operated
Untreated HF Dogs
CCM-Treated
HF Dogs
VFRF (%) 0.0 14.3 1.5* 11.0 0.8*†
VFIF (%) 3.7 0.1 11.2 0.3* 9.4 0.7*†
MCSA (m2) 409 10 719 36* 581 28*†
CD (# capillaries/mm2) 2,607 80 1,882 67* 2,192 117*†
CD (# capillaries/fiber) 1.00 0.0 0.92 0.02* 1.03 0.02*†
ODD (m) 8.9 0.2 11.7 0.3* 10.2 0.2*†
p  0.05 versus normal dogs; †p  0.05 versus sham-operated dogs.
CCM  cardiac contractility modulation electrical signals; CD  capillary density; HF  heartm-Opfter I
dings
3 M
gs
p
0
0
0ailure; MCSA  cardiomyocyte cross-sectional area; ODD  oxygen diffusion distance; VFIF 
olume fraction of interstitial fibrosis; VFRF  volume fraction of replacement fibrosis.
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CCM Therapy in HF May 29, 2007:2120–8oth the interventricular septum and the LV free wall
Table 5).
hronic CCM therapy in combination with beta-
lockade. Ventriculographic results obtained at PRE and
OST are shown in Table 6. Heart failure control animals
OST showed a significant increase in LV EDV and ESV
nd a decrease in EF. Dogs treated with MET-ER alone
howed a small reduction in LV EDV and a significant
ecrease in LV ESV while EF increased. Directionally
imilar results were seen with combination therapy of
ET-ER and CCM (Table 6). Treatment effect analysis
howed a significantly greater improvement of LV ESV and
F in dogs treated with a combination of MET-ER and
CM compared with dogs treated with MET-ER alone
Table 6).
Histomorphometric results are shown in Table 7. Vol-
me fraction of replacement fibrosis, VFIF, MCSA, and
DD were significantly higher in HF control animals
ompared with normal dogs while CD was lower. Mono-
herapy with MET-ER reduced, albeit in part, VFRF,
FIF, MCSA, and ODD and increased CD (Table 7).
Figure 2 Expression of Sarcoplasmic Reticulum Proteins in LV
(Left) Western blots of sarcoplasmic reticulum proteins in tissue obtained from th
(Sham), and 2 cardiac contractility modulation (CCM)-treated dogs. (Right) Wester
of the same dogs as in the left panel. CSQ  calsequestrin; PLB  phospholamb
mRNA and Protein Expression of Fetal ProgramProteins in Lef Ventricular Free Wall
Table 4 mRNA and Protein Expression of FeProteins in Left Ventricular Free Wa
mRNA Expression (du)
NL Sham C
1-AR 22 1 11 1* 18
-MHC 212 7 148 10* 180
ANP 18 2 34 2* 27
BNP 23 3 177 4* 44
SERCA-2a 236 4 154 4* 192
PLB 232 8 149 8* 212
RyR 38 2 22 2* 36
CSQ 264 5 275 5 259
GAPDH 219 6 223 8 236
*p  0.05 versus normal dogs (NL); †p  0.05 versus sham.
ANP  A-type natriuretic peptide; AR  adrenergic receptor; BNP 
signals; CSQ calsequestrin; du densitometric units; GAPDH glys
phospholamban; RyR  ryanodine receptor; SERCA-2a  sarcoplasmombination therapy elicited a significantly greater im-
rovement in VFIF, MCSA, CD, and ODD compared
ith MET-ER alone (Table 7).
Expression of SR proteins in the LV free wall is shown in
able 7. Compared with normal dogs, HF control animals
howed decreased expression of SERCA-2a, RYR, P-PLB
t serine-16, and P-PLB at threonine-17 with no change is
SQ or total PLB. Monotherapy with MET-ER signifi-
antly increased the expression of SERCA-2a, RYR, and
-PLB at serine-16 and threonine-17 again without a
hange in CSQ or total PLB. Combination therapy signif-
cantly increased the expression of P-PLB at serine-16 and
hreonine-17 above that seen with MET-ER alone (Fig. 4)
ut did not increase further the expression of SERCA-2a
nd RYR (Table 7).
cute delivery of CCM therapy. Compared with baseline,
ontinuous delivery of CCM therapy for 2 h increased LV
F (31  2% vs. 26  1%, p  0.05). Compared with
ntreated HF dogs, the ratio of P-PLB to total PLB
ncreased significantly in CCM-treated HF dogs compared
ith untreated HF dogs in the LV anterior wall at the site
ardium
ventricular septum of 2 normal dogs (NL), 2 sham-operated heart failure dogs
of the same proteins in tissue obtained from the left ventricular (LV) free wall
R  ryanodine receptor; SERCA-2a  sarcoplasmic reticulum calcium ATPase.
arcoplasmic Reticulum Genes/
rogram and Sarcoplasmic Reticulum Genes/
Protein Expression (du)
NL Sham CCM
† 102 9 62 10* 89 7†
† — — —
† 88 7 147 23* 63 6†
† 65 10 91 4* 73 3†
† 88 7 54 4* 73 8†
446 19 277 12* 299 9*
126 8 88 5* 106 9†
43 3 40 1 44 3
— — —
natriuretic peptide; CCM  cardiac contractility modulation electrical
yde-3-phosphate dehydrogenase; MHCmyosin heavy chain; PLB
lum calcium ATPase.Myoc
e inter
n blots
an; RYand S
tal P
ll
CM
 1*
 5*
 1*
 5*
 3*
 7†
 5†
 14
 4
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May 29, 2007:2120–8 CCM Therapy in HFf signal delivery (Fig. 5), whereas it was essentially un-
hanged in the LV posterior wall remote from the site of
CM signal delivery (Fig. 6).
iscussion
esults of this study indicate that in dogs with HF,
ong-term therapy with CCM electrical signals improves
lobal LV function and attenuates global LV remodeling.
ardiac contractility modulation therapy also reverses many
f the structural, biochemical, and molecular changes seen
n untreated HF dogs. Results of the study also indicate that
CM therapy provides additive improvement when used on
op of beta-blockade. Dogs treated with a combination of
ET-ER and CCM showed a greater increase in LV EF
nd a greater reversal of LV global, structural, and biochem-
cal remodeling compared with dogs treated with MET-ER
lone.
echanisms of action of CCM therapy. Early studies of
he mechanisms of action of CCM therapy were limited to
cute signal application and focused on the potential impact
Figure 3 Protein Expression of PLB in LV Myocardium
(Top) Western blots of PLB in tissue obtained from the interventricular septum of
(HF  CCM). (Bottom) Western blots of the same protein in tissue obtained from
pholamban; Ser-16  serine-16; Thr-17  threonine-17; Total-PLB  total cardiac
rotein Expression of Total PLB and P-PLB at Ser-16 and Thr-17 in
Table 5 Protein Expression of Total PLB and P-PLB at Ser-16 a
Interventricular Septum
NL Sham
Total PLB (du) 445 7 305 23*
P-PLB Ser-16 (du) 85 6 47 5*
P-PLB Thr-17 (du) 146 6 62 10*
P-PLB Ser-16/total PLB 0.19 0.01 0.15 0.01*
P-PLB Thr-17/total PLB 0.33 0.01 0.21 0.04*p  0.05 versus NL; †p  0.05 versus sham.
CCM  cardiac contractility modulation electrical signals; P-PLB  phosphorylated phospholamban; Sf CCM signals on action potential configuration, which
nly secondarily acts to enhance calcium loading of the SR
25,26). The increase in calcium was assumed to be the sole
ause of the increase in contractility. Furthermore, the acute
mpact of CCM signals on contractile strength was shown
o be limited to only the region of signal application. Thus,
he results of the present studies significantly extend under-
tanding of the effects of CCM signals in several ways. First,
n the acute setting, CCM signals induce changes in gene
xpression. Indeed, significant prior research (27) has shown
n in-vitro model systems that low-frequency, low-intensity
lectromagnetic fields can within minutes induce gene
xpression. It has been suggested that electromagnetic fields
ccelerate electron transfer reactions, which could, in turn,
timulate transcription by interacting with electrons in
NA to destabilize the hydrogen bonds holding the 2
NA strands together. Evidence also suggests that electro-
agnetic fields are more effective in stimulating transcrip-
ion when the fields are applied repeatedly at frequencies
hat coincide with the natural rhythms of the processes
2 sham-operated heart failure dogs (HF-Sham), and 2 CCM-treated HF dogs
free wall of the same dogs as in the top panel. P-PLB  phosphorylated phos-
holamban; other abbreviations as in Figure 2.
nterventricular Septum and LV Free Wall
r-17 in the Interventricular Septum and LV Free Wall
LV Free Wall
CM NL Sham CCM
16* 446 19 305 19* 299 9*
6† 128 11 50 12* 87 11*†
12† 137 4 56 7* 109 18†
0.02† 0.29 0.03 0.16 0.03* 0.29 0.04†
0.05† 0.31 0.02 0.19 0.03* 0.36 0.05†2 NL,
the LV
phospthe I
nd Th
C
299
79
129
0.27
0.44er-16  serine-16; Thr-17  theonine-17; other abbreviations as in Tables 1 and 4.
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CCM Therapy in HF May 29, 2007:2120–8ffected (27). It is notable, therefore, that CCM signals are
pplied repeatedly (several hours per day) and in synchrony
ith the native heart beat. Changes in gene expression are
nlikely to have acute functional effects since protein syn-
hesis takes considerably longer time to occur. However,
asic research has also shown that electromagnetic fields can
lso modify enzyme reactions. Interestingly, another acute
ffect identified in the present study is enhanced phosphor-
lation of PLB within as little as 2 h of signal application.
n this case, the already existing PLB protein is being
hosphorylated rather than synthesis of new protein. Phos-
horylation of PLB enhances SR calcium sequestration by
nhancing the activity and/or affinity of SERCA-2a for
alcium. In turn, this enhances intracellular calcium cycling
apacity and, hence, contractility. Finally, changes in intra-
ellular calcium have themselves been linked to alterations
n gene expression (28). Thus, there are at least 3 synergistic
echanisms by which CCM signals could immediately
mpact functional properties of cardiomyocytes in the region
f signal application, which could mediate functional
hanges in the short and long term.
ffects of CCM therapy on LV remodeling. During
hronic CCM therapy, normalization of gene expression
ay be a primary mechanism of functional improvements
hat may overshadow the impact on improved SR calcium
Angiographic Findings
Table 6 Angiographic Findings
HF Control Animals
PRE POST
LV EDV (ml) 60 1 64 1*
LV ESV (ml) 39 1 45 1*
LV EF (%) 36 1 31 1*
Treatment effect
 LV EDV (ml) 3.7 0.8
 LV ESV (ml) 5.8 0.8
 LV EF (%) 5.3 0.7
*p  0.05 PRE versus POST; †p0.05 versus heart failure (HF) contr
BB  beta-blocker; other abbreviations as in Table 1.
Histomorphometric Findings and Expression of SCycling Proteins n Left Ventricular Myocardium
Table 7 Histomorphometric Findings and ExCycling Proteins in Left Ventricular
NL HF Co
VFRF (%) 0.0 12
VFIF (%) 3.7 0.1 14
MCSA (m2) 409 10 67
CD (# capillaries/mm2) 2607 80 175
CD (# capillaries/fiber) 1.00 0.0 0.8
ODD (m) 8.9 0.2 11
SERCA-2a (du) 352 12 23
Total PLB (du) 79 3 7
RyR (du) 62 2 4
CSQ (du) 371 15 35
P-PLB Ser-16 (du) 97 8 6
P-PLB Thr-17 (du) 127 3 7*p  0.05 versus NL; †p  0.05 versus heart failure (HF) control animals; ‡p
BB  beta-blocker; CCM  cardiac contractility modulation; other abbreviaycling identified in the short term. After chronic CCM
herapy, molecular effects identified locally after acute CCM
ignal application are present in remote myocardium. These
re also associated with reversal of cellular as well as
tructural remodeling. Remote effects may also be mediated
y at least 2 mechanisms. First, the heart is a syncytium in
hich cardiomyocytes are connected by gap junctions,
eaning that the intracellular environment of cells in 1
egion can be transmitted to remote regions. Thus, over
onger periods of time, local changes in intracellular envi-
onment may propagate to remote regions. Second, it has
een shown that the acute effects of CCM therapy impact
nough myocardium so as to enhance global LV function
8–10). If sustained over long periods of time, enhanced LV
hamber contractility results in an overall more favorable
emodynamic state and mechanical loading condition on all
ardiomyocytes. These factors would work secondarily to
romote reverse remodeling of the myocardium in all
egions of the heart, not just the region where CCM signals
re delivered.
CM therapy and beta-blockade. Therapeutic HF strat-
gies such as beta-adrenergic blockade and cardiac resyn-
hronization are associated with improved LV systolic
unction without an increase in MVO2 and are each associ-
ted with improved outcomes (6,29). The abnormal gene
HF  BB HF  BB  CCM
RE POST PRE POST
 4 62 5 70 4 69 4
 2 36 4* 45 3 36 3*
 1 42 2* 36 1 48 1*
1.3 1.0† 0.9 1†
4.3 1.0† 7.9 0.6†‡
6.2 1.0† 11.1 0.6†‡
als; ‡p  0.05 versus HF  BB.
plasmic Reticulum Calcium
ion of Sarcoplasmic Reticulum Calcium
ardium
nimals HF  BB HF  BB  CCM
.5* 10.1 1.7*† 10.3 1.1*†
.0* 9.7 0.4*† 7.8 0.2*†‡
6* 562 5*† 506 4*†‡
6* 2216 25*† 2373 18*†
.03* 1.07 0.02*† 1.08 1*†
.3* 10.5 0.2*† 10.4 0.2†‡
0* 321 13† 422 35*†‡
73 3 77 3
* 59 1† 62 3†
362 17 383 13
* 77 1*† 91 4†‡
* 91 2*† 110 6*†‡P
64
41
36arco
press
Myoc
ntrol A
.9 1
.2 1
4 2
6 7
7 0
.8 0
8 1
2 2
5 2
8 8
5 2
0 2 0.05 versus HF  BB.
tions as in Tables 3, 4, and 5.
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May 29, 2007:2120–8 CCM Therapy in HFxpression profile of HF, which recapitulates the fetal gene
rogram, is reversed by beta-blocker treatment (30) as was
lso the case in the present study. As detailed in the
receding text, the impact of CCM treatment in this animal
odel of HF from a functional and remodeling perspective
ost closely mimics the impact of the beneficial effects seen
ith beta-blockers and cardiac resynchronization therapy.
esults of the present study further indicate that CCM
herapy can provide improvements in LV function and LV
hamber remodeling that are additive to those seen with
eta-blockade alone. This is particularly true with respect to
R calcium cycling protein and, in particular, PLB
hosphorylation.
Figure 4 Protein Expression of PLB in LV Myocardium of Dogs
Western blots of Total-PLB, P-PLB at Ser-16, and P-PLB at Thr-17 in tissue obtained fro
treated with beta-blockade only (HF  beta-blocker [BB]), and 2 HF dogs treated w
Figure 5 Ratio of P-PLB to Total PLB in the LV Anterior Wall
(Top) Bar graph (mean  SEM) depicting the ratio of P-PLB/Total PLB in LV
anterior wall of 6 NL, 6 untreated HF dogs, and 6 CCM-treated HF dogs (HF 
CCM). (Bottom) Western blots of P-PLB and Total-PLB in tissue obtained from
the LV anterior wall of 2 NL, 2 untreated HF dogs, and 2 CCM-treated HF dogs
(HF  CCM). Abbreviations as in Figures 2 and 3.tudy limitations. There are some study limitations that
erit consideration. The study focused on identification of
lteration in myocardial gene and protein expression during
oth acute (2 h) as well as chronic (3 months) delivery of
CM therapy. It remains uncertain, therefore, whether
iochemical and molecular changes observed in myocardial
egions remote from the site of CCM signal delivery
equired days, weeks, or months to manifest themselves.
he CCM signal characteristics were chosen to be identical
o those being used in ongoing clinical trials. Thus, it is not
nown if the observed effects can be enhanced if signal
arameters such as amplitude, duration, and frequency are
odified. The current study is limited to observation of
ed With a BB
LV free wall of 2 NL, 2 control untreated HF dogs (HF-Control), 2 HF dogs
h BB and CCM (HF  BB  CCM). Abbreviations as in Figures 2 and 3.
Figure 6 Ratio of P-PLB to Total-PLB in the LV Posterior Wall
(Top) Bar graph (mean  SEM) depicting the ratio of P-PLB/Total-PLB in LV
posterior wall of 6 NL, 6 untreated HF dogs, and 6 CCM-treated HF dogs (HF 
CCM). (Bottom) Western blots of P-PLB and Total-PLB in tissue obtained from
the LV posterior wall of 2 NL, 2 untreated HF dogs, and 2 CCM-treated HF
dogs (HF  CCM). Abbreviations as in Figures 2 and 3.Treat
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CCM Therapy in HF May 29, 2007:2120–8hanges in expression and phosphorylation of only a small
umber of proteins that are abnormal in HF. The impact of
CM therapy on a host of other genes and proteins affected
n HF is not addressed. While results of studies point to a
ossible role of PLB phosphorylation and perhaps reversal
f the maladaptive fetal gene program as possible mecha-
isms of action of this form of therapy, additional studies
re needed to demonstrate a cause and effect relationship.
onclusions
hronic CCM signal application in a clinically relevant
nimal model of HF is associated with marked improve-
ent of global LV function and reversal of LV chamber
emodeling both globally and at the cellular and molecular
evels. The improvements are additive to those seen with
eta-blockers. Cardiac contractility modulation therapy in
his animal model of HF also reverses expression of genes
nown to be maladaptive in HF and was clearly associated
ith improved phosphorylation of PLB. The latter, along
ith improved expression of SERCA-2a, also a finding of
his study, is integral to improvement of SR calcium cycling
ithin cardiomyocytes and, hence, improved contractile
erformance. Confirmation of the clinical benefits of this
nvestigational therapy, however, must await completion of
ngoing clinical trials in patients with advanced HF.
eprint requests and correspondence: Dr. Hani N. Sabbah,
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